Today
- Live
- Markets Live
ASX falls; Pacific Smiles rallies; gold, lithium miners drop
Shares retreat after late US sell-off; Pacific Smiles turns down “undervalued” bid; $A eases to US67.37¢; global bond yields drop after UK inflation print; oil holds three-day gain. Follow updates here.
- 20 mins ago
- Timothy Moore, Sarah Jones, Joanne Tran and Cecile Lefort
ASX to fall, S&P 500 rally runs out of petrol
Australian shares are set to open lower. US stocks sell-off late; Dow sheds 475 points. S&P 500 slides 1.5pc.
- Updated
- Timothy Moore
Apple to reach $US4 trillion value in 2024: Wedbush
Dan Ives calls the dispute involving the tech giant’s watches, which has dented the stock’s rise this week, a “headache issue” that will be resolved soon.
- Timothy Moore
Tesla is getting trounced by S&P 500 three years after joining
The EV car maker’s shares have risen about 11 per cent since entering the benchmark US index, which itself has surged 28 per cent over the same time.
- Esha Dey
Yesterday
Global shift in rate cut bets sparks Santa rally
A “dovish” pivot from the Fed last week has lit a fire under equities, which have correctly bet that global monetary settings are shifting gear.
- Updated
- Sarah Jones and Cecile Lefort
- Opinion
- Investing
Making sense of the December market madness
Equities are on fire and Australian investors are enjoying a broad-based rally in stocks that may just be getting started.
- Jonathan Shapiro
- Opinion
- Chanticleer
Rally has more room to run as investors get three green lights
The market has built a head of steam in the last two months, and until there’s a clear risk to the Goldilocks soft landing scenario there is little reason for the bulls to turn.
- James Thomson
Investors tip strong payouts from sin-binned coal stocks
The coal sector is consolidating as big miners sell assets at bargain prices to juniors that can potentially grow resources and balance dividend payouts.
- Tom Richardson
- Opinion
- Chanticleer
The good, bad and ugly of business in 2023
Big deals, dud deals, scandals and success stories. In a year of high drama and big market moves, we look back at the winners and losers.
- Updated
- James Thomson
ASX rallies; KMD, PEXA tumble; consumer stocks jump
Shares advance, tracking gains on Wall Street; oil rises; Orica buys Canadian company for $560 million; KMD Brands sales slide; $A rises. Follow updates here.
- Updated
- Timothy Moore, Joanne Tran, Cecile Lefort and Sarah Jones
ASX to rise, S&P 500 edges closer to record high
Australian shares are set to open higher. Dow, Nasdaq 100 reset record highs. Fed official signals rate cut potential. Oil edges towards $US80 mark. $A rises.
- Timothy Moore
Global fund mangers extend their equity bets
Fund managers are the most overweight equities relative to cash since January 2022, according to Bank of America’s latest survey of their holdings.
- Timothy Moore
This Month
Fed’s pivot forces sharemarket sceptics to become believers
Rate cut talk from the Federal Reserve last week has forced even the most steadfast Wall Street bears into changing their tune on US equities.
- Alexandra Semenova
ASX charges ahead, Rio closes at record high
Shares rally; AGL plans $750m battery plant, Propel Funeral expands; Apple slips on patent loss, Azure gets sweeter bid, Origin spends big in UK. Follow updates here.
- Updated
- Timothy Moore, Cecile Lefort, Joanne Tran and Sarah Jones
ASX to rise, Wall Street powers higher
Australian shares are set to advance. S&P 500 paces gains in New York. Oil retakes $US78 mark. $A steady. Apple lower on Watch patent loss.
- Timothy Moore
Zoom dropped from Nasdaq in sign pandemic-era darling trade is over
Shares in the video-conferencing company have underperformed every major equity benchmark in 2023, rising just 5.7 per cent.
- Emily Graffeo and Brody Ford
- Opinion
- Wall Street
The Fed runs a fool’s errand on bank capital rules
Finding a risk model that captures potential embezzlement, consumer abuse and money laundering losses is no easy task.
- Marc Rubinstein
Biotech sensation Neuren rallies to record on clinical trial results
Neuren has developed a drug that treats neurological disorders in children to improve hand movement and communication.
- Tom Richardson
- Opinion
- Chanticleer
What’s behind Monday’s $5b deal frenzy
A burst of pre-Christmas deals isn’t unusual. But the impressive market rally in the past six weeks has helped unstick some deals that have been simmering for some time.
- James Thomson
It’s the ‘new lithium’: Uranium tipped to extend bull run into 2024
A COP28 pledge to triple nuclear capacity and China’s plans to build 154 new reactors point to higher prices for the strategic commodity, say analysts.
- Tom Richardson
